Crystalline forms of tryosine kinase inhibitors and their salts
AssigneeVM Pharma LLC
InventorsJay Jie-Qiang Wu, Ling Wang
Life of this patent
Estimating the term…
Abstract
The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
Claims21
A method of treating a patient for a disease, disorder, or condition associated with NGF induced activation of a TrkA receptor, comprising:
- administering to a patient in need thereof, a crystalline polymorph Form A of Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, with the following structure:
- characterized by having x-ray powder diffraction pattern peak positions at degree two-theta of 10.0±0.3, 20.1±0.3, and 23.6±0.3,
- wherein said disease, disorder, or condition is at least one selected from the group consisting of:
- cancer, restenosis, atherosclerosis, psoriasis, thrombosis, skin disease, inflammation, inflammation related disease, and conditions associated with dysmyelination or demyelination.
A method of treating a patient for a disease, disorder, or condition associated with NGF induced activation of a TrkA receptor, comprising:
- administering to a patient in need thereof, a crystalline polymorph Form A of compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, with the following structure:
- characterized by having an x-ray powder diffraction pattern exhibiting three or more peak positions at degree two-theta selected from the group consisting of:
- 7.160, 8.757, 9.820, 10.161, 12.459, 14.641, 15.219, 17.680, 18.240, 19.104, 20.220, 21.381, 22.579, 23.721, 24.898, 25.761, 25.522, 27.161, 28.321, 29.481, 30.921, and 34.281,
- wherein said disease, disorder, or condition is at least one selected from the group consisting of:
- cancer, restenosis, atherosclerosis, psoriasis, thrombosis, skin disease, inflammation, inflammation related disease, and conditions associated with dysmyelination or demyelination.
A method of treating a patient for a disease, disorder, or condition associated with NGF induced activation of a TrkA receptor, comprising:
- administering to a patient in need thereof, a combination, comprising:
- a) a crystalline polymorph Form A of Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, with the following structure:
- characterized by having x-ray powder diffraction pattern peak positions at degree two-theta of 10.0±0.3, 20.1±0.3, and 23.6±0.3;
- or
- b) a combination of said crystalline polymorph Form A of Compound I and an amorphous form of Compound I;
- and
- one or more pharmaceutically acceptable excipients.
A method of treating a patient for a disease, disorder, or condition associated with NGF induced activation of a TrkA receptor, comprising:
- administering to a patient in need thereof, a solid or semi-solid dosage form, comprising:
- a) a crystalline polymorph Form A of Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, with the following structure:
- characterized by having x-ray powder diffraction pattern peak positions at degree two-theta of 10.0±0.3, 20.1±0.3, and 23.6±0.3;
- or
- b) a combination of said crystalline polymorph Form A of Compound I and an amorphous form of Compound I.
Dependencies are inferred from the claim text.